全文获取类型
收费全文 | 597980篇 |
免费 | 30834篇 |
国内免费 | 3292篇 |
专业分类
耳鼻咽喉 | 8383篇 |
儿科学 | 16383篇 |
妇产科学 | 16646篇 |
基础医学 | 81837篇 |
口腔科学 | 18460篇 |
临床医学 | 48229篇 |
内科学 | 117894篇 |
皮肤病学 | 13526篇 |
神经病学 | 41550篇 |
特种医学 | 25333篇 |
外国民族医学 | 179篇 |
外科学 | 92211篇 |
综合类 | 11306篇 |
现状与发展 | 2篇 |
一般理论 | 101篇 |
预防医学 | 36298篇 |
眼科学 | 14282篇 |
药学 | 46067篇 |
3篇 | |
中国医学 | 2448篇 |
肿瘤学 | 40968篇 |
出版年
2018年 | 8841篇 |
2017年 | 7844篇 |
2016年 | 7270篇 |
2015年 | 9372篇 |
2014年 | 10690篇 |
2013年 | 11966篇 |
2012年 | 21486篇 |
2011年 | 16799篇 |
2010年 | 9322篇 |
2009年 | 10423篇 |
2008年 | 12999篇 |
2007年 | 14596篇 |
2006年 | 14669篇 |
2005年 | 21566篇 |
2004年 | 22552篇 |
2003年 | 17820篇 |
2002年 | 12727篇 |
2001年 | 32870篇 |
2000年 | 30890篇 |
1999年 | 29643篇 |
1998年 | 5891篇 |
1997年 | 4691篇 |
1996年 | 4389篇 |
1995年 | 4017篇 |
1994年 | 3578篇 |
1992年 | 23112篇 |
1991年 | 22143篇 |
1990年 | 21775篇 |
1989年 | 21092篇 |
1988年 | 19284篇 |
1987年 | 18566篇 |
1986年 | 17329篇 |
1985年 | 15826篇 |
1984年 | 10695篇 |
1983年 | 8678篇 |
1982年 | 3855篇 |
1979年 | 9480篇 |
1978年 | 5872篇 |
1977年 | 4874篇 |
1976年 | 3894篇 |
1975年 | 5217篇 |
1974年 | 6293篇 |
1973年 | 5713篇 |
1972年 | 5666篇 |
1971年 | 5598篇 |
1970年 | 5138篇 |
1969年 | 5091篇 |
1968年 | 4557篇 |
1967年 | 4172篇 |
1966年 | 3771篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
Y. Ermias I.A. Morgan K.M. Curtis M.K. Whiteman L.G. Horton L.B. Zapata 《Contraception》2019,99(5):300-305
ObjectiveIdentify factors associated with healthcare providers' frequency of depot medroxyprogesterone acetate (DMPA) provision to adolescents.Study designWe analyzed data from surveys mailed to a nationally representative sample of public-sector providers and office-based physicians (n=1984). We estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) of factors associated with frequent DMPA provision to adolescents in the past year.ResultsAlthough most providers (>95%) considered DMPA safe for adolescents, fewer reported frequent provision (89% of public-sector providers; 64% of office-based physicians). Among public-sector providers, factors associated with lower odds of frequent provision included working in settings without Title X funding (aOR 0.44, 95% CI 0.30–0.64), reporting primary care as their primary clinical focus versus reproductive or adolescent health (aOR 0.42, 95% CI 0.28–0.61), and providing fewer patients with family planning services. Among office-based physicians, factors associated with lower odds of frequent provision included specializing in obstetrics/gynecology (aOR 0.50, 95% CI 0.27–0.91) and family medicine (aOR 0.21, 95% CI 0.09–0.47) versus adolescent medicine, completing training ≥15 versus <5 years ago (aOR 0.27, 95% CI 0.09–0.83), and reporting that 0–24% of patients pay with Medicaid or other government healthcare assistance versus ≥50% (aOR 0.23, 95% CI 0.09–0.61). The reason most commonly reported by providers for infrequent DMPA provision was patient preference for another method.ConclusionsWhile most providers reported frequently providing DMPA to adolescents, training on evidence-based recommendations for contraception, focused on subgroups of providers with lower odds of frequent DMPA provision, may increase adolescents' access to contraception.ImplicationsAlthough >95% of providers considered depot medroxyprogesterone (DMPA) a safe contraceptive for adolescents, only 89% of public-sector providers and 64% of office-based physicians reported frequently providing DMPA to adolescents. Provider training on evidence-based recommendations for contraception counseling and provision may increase adolescents' access to DMPA and all methods of contraception. 相似文献
43.
44.
Prevention Science - This study aimed to evaluate the effectiveness of the drug and violence resistance educational program (PROERD) on short-term secondary outcomes, such as intentions to use... 相似文献
45.
46.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献47.
48.
Adilson Cunha Ferreira Edward Araujo Júnior Wellington P. Martins João Francisco Jordão Antônio Hélio Oliani Simon E. Meagher 《The journal of maternal-fetal & neonatal medicine》2015,28(14):1706-1710
Objective: To assess the quality of images and video clips of fetal central nervous (CNS) structures obtained by ultrasound and transmitted via tele-ultrasound from Brazil to Australia.Methods: In this cross-sectional study, 15 normal singleton pregnant women between 20 and 26 weeks were selected. Fetal CNS structures were obtained by images and video clips. The exams were transmitted in real-time using a broadband internet and an inexpensive video streaming device. Four blinded examiners evaluated the quality of the exams using the Likert scale. We calculated the mean, standard deviation, mean difference, and p values were obtained from paired t tests.Results: The quality of the original video clips was slightly better than that observed by the transmitted video clips; mean difference considering all observers = 0.23 points. In 47/60 comparisons (78.3%; 95% CI?=?66.4–86.9%) the quality of the video clips were judged to be the same. In 182/240 still images (75.8%; 95% CI?=?70.0–80.8%) the scores of transmitted image were considered the same as the original.Conclusion: We demonstrated that long distance tele-ultrasound transmission of fetal CNS structures using an inexpensive video streaming device provided images of subjective good quality. 相似文献
49.
50.